^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)

    i
    Other names: SIGLEC9, Sialic Acid Binding Ig Like Lectin 9, CD329, Sialic Acid-Binding Ig-Like Lectin 9, Protein FOAP-9, Siglec-9, CDw329, Sialic Acid Binding Ig-Like Lectin 9, CD329 Antigen, OBBP-LIKE, FOAP-9
    Associations

    News

    Trials
    2ms
    The role of SIGLEC9 in immunosuppression and prognosis in cervical cancer. (PubMed, Clinics (Sao Paulo))
    SIGLEC9 plays a crucial role in the progression and prognosis of cervical cancer through its interaction with TAMs and T-cells. These findings highlight SIGLEC9 as a potential target for new immunotherapies in CC.
    Journal • IO biomarker
    |
    MUC1 (Mucin 1) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    2ms
    RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma. (PubMed, Cancer Biol Ther)
    Although lenalidomide/bortezomib/dexamethasone (RVd) and cyclophosphamide/bortezomib/dexamethasone (CyBorD) are clinically effective, their precise impacts on PC/B-cell maturation remain unclear. RVd responders further downregulated CD56, CD269, and CD329, and increased CD243. These shared and divergent modulations elucidate the molecular underpinnings of RVd and CyBorD efficacy and inform precision regimen selection.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • TNFRSF17 (TNF Receptor Superfamily Member 17) • RARA (Retinoic Acid Receptor Alpha) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • PAX5 (Paired Box 5) • KLF4 (Kruppel-like factor 4) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD200 (CD200 Molecule) • IRF4 (Interferon regulatory factor 4) • CD52 (CD52 Molecule) • PRDM1 (PR/SET Domain 1) • NANOG (Nanog Homeobox) • NES (Nestin) • XBP1 (X-box-binding protein 1) • CD81 (CD81 Molecule) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • SLAMF7 (SLAM Family Member 7) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    |
    lenalidomide • bortezomib • cyclophosphamide
    8ms
    Identification of an Immune-Related Gene Signature for Prognostic Prediction in Glioblastoma: Insights from Integrated Bulk and Single-Cell RNA Sequencing. (PubMed, Cancers (Basel))
    This Macrophage-Associated Prognostic Signature (MAPS) provides new insights into glioblastoma immunobiology and identifies potential biomarkers and therapeutic targets. It may serve as a valuable tool to guide personalized immunotherapy-based strategies for glioblastoma patients.
    Journal • Gene Signature • IO biomarker
    |
    THEMIS2 (Thymocyte Selection Associated Family Member 2) • MS4A6A (Membrane Spanning 4-Domains A6A) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    12ms
    Mendelian randomization identifies proteins involved in neurodegenerative diseases. (PubMed, Brain)
    The newly associated proteins indicated the involvement of complement (C1S and C1R), microglia (SIRPA, SIGLEC9 and PRSS8) and lysosomes (CLN5) in Alzheimer's disease; the interleukin-6 pathway (CTF1) in Parkinson's disease; lysosomes (TPP1), blood-brain barrier integrity (MFAP2) and astrocytes (TNFSF13) in amyotrophic lateral sclerosis; and blood-brain barrier integrity (VEGFB), oligodendrocytes (PARP1), node of Ranvier and dorsal root ganglion (NCS1, FLRT3 and CDH15) and the innate immune system (CR1, AHSG and WARS) in multiple sclerosis. Our study demonstrates how harnessing large-scale genomic and proteomic data can yield new insights into the role of the plasma proteome in the pathogenesis of neurodegenerative diseases.
    Journal
    |
    IL6 (Interleukin 6) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • VEGFB (Vascular Endothelial Growth Factor B) • APOE (Apolipoprotein E) • PILRA (Paired Immunoglobin Like Type 2 Receptor Alpha) • AHSG (Alpha 2-HS Glycoprotein) • SIRPA (Signal Regulatory Protein Alpha) • TNFSF13 (TNF Superfamily Member 13) • TPP1 (Tripeptidyl Peptidase 1) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    1year
    Potential drug targets for ovarian cancer identified through Mendelian randomization and colocalization analysis. (PubMed, J Ovarian Res)
    This study provides proof of a causal relationship between genetically predicted 44 proteins associated with OC risk, which could serve as promising drug targets for OC.
    Journal
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • IL1R1 (Interleukin 1 receptor, type I) • IL6ST (Interleukin 6 Signal Transducer) • LRRC1 (Leucine Rich Repeat Containing 1) • PDIA3 (Protein Disulfide Isomerase Family A Member 3) • SPINK1 (Serine peptidase inhibitor, kazal type 1) • TGFBI (Transforming Growth Factor Beta Induced) • CNTN2 (Contactin 2) • CPNE1 (Copine 1) • PLAU (Plasminogen Activator) • SEMA4D (Semaphorin 4D) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    1year
    Association of SIGLEC9 Expression with Cytokine Expression, Tumor Grading, KRAS, NRAS, BRAF, PIK3CA, AKT Gene Mutations, and MSI Status in Colorectal Cancer. (PubMed, Curr Issues Mol Biol)
    SIGLEC9 expression was significantly associated with the expression of multiple cytokines, chemokines, and growth factors in the CRC TME. These associations suggest the significant potential of SIGLEC9 as a molecule that plays a crucial role in shaping the immune properties of the CRC TME, as well as its potential therapeutic relevance, particularly in the group of high-grade CRC tumors.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • KRAS expression
    over1year
    Prognostic and immune infiltration implications of SIGLEC9 in SKCM. (PubMed, Diagn Pathol)
    Additionally, our analysis of single-cell transcriptome data revealed that SIGLEC9 not only played a role in the normal skin immune microenvironment, but is also highly expressed in immune cell subpopulations of SKCM patients, regulating the immune response to tumors. Our findings suggest that the close association between SIGLEC9 and SKCM prognosis is primarily mediated by its effect on the tumor immune microenvironment.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    almost2years
    Siglec9 + tumor-associated macrophages predict prognosis and therapeutic vulnerability in patients with colon cancer. (PubMed, Int Immunopharmacol)
    Siglec9 + TAMs may serve as a biomarker for prognosis and response to ACT in CC. Furthermore, the immunoevasive contexture and angiogenesis stimulated by Siglec9 + TAMs suggest potential treatment combinations for CC patients.
    Journal
    |
    CD8 (cluster of differentiation 8) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    |
    VEGFA overexpression • VEGFA expression
    2years
    Single-cell RNA-seq reveals the metabolic status of immune cells response to immunotherapy in triple-negative breast cancer. (PubMed, Comput Biol Med)
    In summary, our research identified specific metabolic 'sub-subtypes' associated with ICB non-response and uncovered the mechanisms of their regulation in TNBC. And the proposed analytical pipeline can be used to examine metabolic heterogeneity within cell types that correlate with diverse phenotypes.
    Journal • Immune cell
    |
    SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    over2years
    Construction and validation of a immune-related prognostic gene DHRS1 in hepatocellular carcinoma based on bioinformatic analysis. (PubMed, Medicine (Baltimore))
    The DHRS1 gene may exert an impact on HCC immunity. We posit that the nominated immune signature based on DHRS1-associated immunomodulators could constitute a promising prognostic biomarker in HCC.
    Journal • IO biomarker
    |
    KDR (Kinase insert domain receptor) • CD276 (CD276 Molecule) • TNFRSF4 (TNF Receptor Superfamily Member 4) • SLAMF6 (SLAM Family Member 6) • TNFSF4 (TNF Superfamily Member 4) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    over2years
    Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response. (PubMed, Nat Cancer)
    Furthermore, Siglece deletion synergized with anti-PD-1/PD-L1 treatment to improve antitumor efficacy. Our data demonstrated that Siglec-9 is an immune-checkpoint molecule on macrophages that can be targeted to enhance anti-PD-1/PD-L1 therapeutic efficacy for GBM treatment.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)